When ‘Too Good to Be True’ Really Is Too Good to Be True: FTC Settles With NextMed Regarding Deceptive Advertising Practices

The Federal Trade Commission (“FTC”) has reached a settlement with NextMed (also known as Southern Health Solutions, Inc.), resolving allegations that the telehealth company misled consumers through deceptive advertising, billing, and cancellation practices tied to weight-loss programs involving GLP-1 medications such as Wegovy and Ozempic. The FTC also named the company’s founder, Robert Epstein and CEO, Frank Leonardo III, in its Complaint. This case underscores how aggressive marketing in the booming prescription weight-loss space can cross into unlawful misrepresentation, eroding consumer